Special Issue

Evaluation of the Antitumor Mechanism of Armed Antibodies

Message from the Guest Editors

After this success in obtaining target-specific mAbs easily, the "missile therapy" or the "immunoconjugate" was developed for clinical use in the late 1980s. In the 1990s, antibody engineering technologies that allowed genetic modification of murine antibodies to produce chimeric mouse-human antibodies or humanized antibodies were developed. From the late 2000s, these mAbs were again applied to the immunoconjugate, named the "antibody drug conjugate". ADCs are categorized as armed antibodies, which means antibodies have the "weapons", and antibodies are used for delivery carriers of the weapons, such as anticancer drugs and radioisotopes. As of August 2020, 9 ADCs and one radioimmunotherapy (RIT) drug have been approved by the FDA. Thus, armed antibodies are one of the most exciting areas for cancer therapeutics. In this Special Issue of Pharmaceuticals, original research, mini-review, and review articles regarding armed antibodies are invited. This Special Issue focuses on the therapeutic antibodies in vitro, in vivo, and clinical studies.

Guest Editors

Dr. Yoshikatsu Koga

Dr. Hiroki Takashima

Dr. Shigehiro Koganemaru

Deadline for manuscript submissions

closed (31 October 2022)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/59173

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

